Skip to main content
. 2022 Jul 13;13(7):607. doi: 10.1038/s41419-022-05057-4

Fig. 1. Clustering and dominant immune cells associated with neoadjuvant response.

Fig. 1

A Flow chart of the overall study design (Figure created with biorender.com.). CD45+ immune cells derived from tumor tissues (T) and five immune-relevant sites (nearest non-cancer tissues (N), regional draining lymph nodes (LN), distal normal tissues (D), peripheral blood mononuclear cells before and after neoadjuvant therapy (hereafter we called P0 and P1)) were applied to single-cell transcriptome/TCR sequencing. B The UMAP projection of 186,477 cells from 12 patients, showing the formation of 29 main clusters, including two for NK/NKT cells, three for B cells and plasma cells, three for CD4+ T cells, six for CD8+ T cells, eight for myeloid clusters and two cycling cells. Each dot corresponds to one single cell, colored according to the cell cluster. C Neoadjuvant patient categories according to their pathologic response, with four patients in MPR and four patients in non-MPR groups. D UMAP displaying of the immune cell composition in treatment-naive, non-MPR and MPR tumor tissues. E Composites of major immune cell proportions in treatment-naive, non-MPR, and MPR tumor tissues.